Background-IL-9-secreting (T H 9) T cells are thought to represent a distinct T-cell subset. However, evidence for their functionality in disease is uncertain.
direct evidence for their existence in vivo is lacking. Although T H 9 cells lack expression of either T bet or GATA-3, the defining transcription factors for T H 1 or T H 2 lineage development, respectively, PU.1 and interferon regulatory factor 4 have both been associated with T H 9 cell differentiation. 9,10 IL-25 maximizes T H 9 differentiation, due to the expression of its receptor, interleukin-17 receptor B (IL-17RB), on the cell surface. 11, 12 Importantly, this pathway was shown to be important for the regulation of IL-9 expression during allergic airway inflammation, since IL-25 deficiency leads to reduced IL-9 expression and airway inflammation. 13 There is a wealth of evidence to show that IL-9 is involved in the development of allergic responses. 5, 14, 15 Many cells are able to secrete IL-9, but the specific cellular source has not been determined in vivo. 16, 17 T H 9 cells have been implicated in the development of disease in the central nervous system, 3 the lung, 10 and the eye 18 ; however, it is not clear how they actually contribute to pathology in these organs. In particular, the specific contribution that T H 9 cells might make during the development of allergic immune responses remains unclear.
The TGF-β superfamily member activin A plays a vital role during allergic responses, promoting enhanced remodeling and airway hyperreactivity (AHR) via interactions with IL-25. 19 This interaction between activin A and IL-25 coupled with the fact that IL-25 maximizes TGF-β1-mediated differentiation of T H 9 cells prompted us to investigate the role of activin A in T H 9 development. We demonstrate that activin A is able to replicate the ability of TGF-β1 to drive T H 9 polarization in vitro and in vivo. Critically, effective suppression of T H 9 function in vivo is entirely reliant on the blockade of both TGF-β and activin A. Our studies show that T H 9 cells have an in vivo function that is distinct, but complementary to that of T H 2 cells, and reveal a novel pathway to T H 9 differentiation that has direct consequences for the development of allergic pathology.
METHODS

Mice
BALB/c and severe combined immunodeficiency mice (6-8 weeks) were purchased from Charles River (Morgate, United Kingdom [UK]). All experiments were performed in accordance with UK Home Office guidelines.
Induction and analysis of allergic airway inflammation
Mice received 15 μg of house dust mite (HDM) extract (Dermatophagoides pteronyssinus in saline; Greer Laboratories, Lenoir, NC) or saline intranasally 3 days a week for 1 or 3 weeks. In adoptive transfer experiments, 1 × 10 6 in vitro generated T H 9 cells (more than 90% CD4 + IL-9 + IL-13 − IFN-γ − ) were injected intraperitoneally. In blocking experiments, mice received 20 μg of neutralizing antibody to murine activin A (R&D Systems, Abingdon, UK) and/or anti-TGF-β (5 mg/kg, clone 1D11 pan neutralizing TGF-β1-3; Genzyme Corporation, Cambridge, Mass) or isotype control intraperitoneally. Serum, bronchoalveolar lavage fluid, lung homogenates, and draining lymph nodes were harvested as previously described. 19 AHR and airway remodeling were assessed as described previously. 19 T H 9 cell differentiation CD3 + CD4 + cells from lymph nodes and spleens were stimulated with plate-bound anti-CD3 (1 μg/mL; BD Pharmingen, Oxford, UK) plus soluble anti-CD28 (2 μg/mL; BD Pharmingen) in the presence of 5 ng/mL of rIL-4 and 1 ng/mL of rTGF-β1 or 20 ng/mL of activin A with or without rIL-25 (10 ng/mL) in IMDM (Sigma, Gillingham, UK) supplemented with 10% FCS (Life Technologies, Carlsbad, Calif). T H 2 cells were differentiated with 10 μg of anti-IFNγ and 10 ng/mL of IL-4. After 4 days, cells were restimulated with 500 ng/mL of ionomycin and 50 ng/mL of phorbol 2-myristate 13-acetate in the presence of brefeldin (BD Pharmingen). Cells were stained for CD4, PU.1 (Cell Signalling Technology, Beverly, Mass), IL-13, IL-10, IL-17, IFN-γ (BD Pharmingen), or IL-9 (Biolegend, San Diego, Calif). T H 9 cells are defined as CD4 + IL-9 + IL-13 − IFN-γ − cells. T H 2 cells are defined as CD4 + IL-13 + . For the detection of IL-17RB surface expression, T cells were stained with anti-IL-17RB, followed by anti-rabbit IgG Alexa488 (Invitrogen, Paisley, UK). Cells from the lung were additionally stained with the following antibodies: anti-GR1, anti-SiglecF (BD Pharmingen), anti-mouse T1/ST2 (Morwell Diagnostics, Zurich, Switzerland), or relevant isotype controls. Labeled cells were acquired on the BD fluorescence-activated cell sorting Aria (BD Bioscience, Oxford, UK) and further analyzed by using FlowJo (Treestar, Ashland, Ore). An equal number of total events were collected for analysis.
Cytokine analysis
Paired antibodies for murine IL-4, IL-5, TGF-β1, and IFN-γ (BD Pharmingen) and IL-25, activin A, IL-33, IL-13 thymic stromal lymphopoietin, CCL20, and IgE (R&D Systems, Minneapolis, Minn) were used in standardized sandwich ELISAs. Human IL-9 ELISA kit was purchased from Peprotech (Rocky Hill, NJ). All presented data have been normalized for tissue weight. Mouse mast cell protease-1 (Moredun, Penicuik, UK) was used according to the manufacturer's protocol.
Immunohistochemistry
Paraffin sections were stained with rabbit anti-mouse tryptase beta 1 (Abcam, Cambridge, UK). Intraepithelial mast cells were scored in the whole lung section (normalized for area), and median of the numbers of intraepithelial mast cells/section was reported.
Quantification of total lung collagen
Recently synthesized acid-soluble collagens were measured in lung tissue by biochemical assay according to the manufacturer's instructions (Sircol collagen assay; Biocolor, Belfast, UK).
Human T H 9 cells
The study was approved by the ethics committee of the Royal Brompton and Harefield Hospitals NHS Trust and was performed with the subjects' written informed consent. Whole blood (50 mL) was collected for the isolation of PBMCs and the measurement of serum IgE level by ELISA. Atopic subjects had self-reported allergies to either pollen or HDM or both. Only those individuals who had not used mediation to treat symptoms of allergy for 4 weeks prior to blood sampling were included in the study. Atopic status was confirmed by elevated serum IgE levels. PBMCs were stimulated as before and analyzed for the expression of PU.1 (Cell Signaling Technology), IL-13, INF-γ, and IL-9 (BD Pharmingen). T H 9 cells are defined as CD4 + IL-9 + IL-13 − IFN-γ − cells.
Statistical analysis
Data were analyzed by using Prism 4 (GraphPad Software Inc, La Jolla, Calif). Data shown represent means ± SEMs of at least 2 independent experiments (n = 6-16). Multiple comparisons were performed by using the Kruskal-Wallis test for nonparametric data, and where statistical differences (P < .05) were observed the data sets were further analyzed by using a paired Mann-Whitney U test. Correlation analysis was performed by using the Spearman test.
RESULTS T H 9 cells are generated in the lungs following exposure to allergen and are associated with atopy in patients
PBMCs isolated from asthmatic children generate greater numbers of T H 9 cells in vitro when compared with nonasthmatic controls. 9 However, direct evidence for the existence of T H 9 cells during an allergic response in vivo is lacking. In order to directly evaluate the T H 9 subset in human subjects, we isolated PBMCs from allergic or nonallergic donors, and quantified them by flow. We found significantly higher numbers of circulating T H 9 cells, defined as CD4 + IL-9 + IL-13 − IFN-γ − , in allergic donors than in nonallergic donors (Fig 1,  A) . Interestingly, circulating numbers of T H 9 cells correlated with levels of IgE in the plasma from these subjects (P = .045; r 2 = 0.50; Fig 1, B) . The ETS-family transcription factor PU.1 is reported to be required for the development of T H 9 cells. 9 However, although a proportion of T H 9 cells from atopic donors do express PU.1, this was not true for all cells (median 52%; range 5%-90% of T H 9 cells) (Fig 1, C) .
The number of T H 9 and T H 2 cells isolated from the lungs of mice exposed to inhaled HDM extract was also determined. CD4 + IL-9 + IL-13 − IFN-γ − IL-17 − cells were only rarely observed in lungs from naive mice; however, inhalation of the environmental allergen HDM led to the early in vivo differentiation of T H 9 cells ( Online Repository at www.jacionline.org for flow plots). We detected maximal numbers of T H 9 cells in both the lungs and airways after 1 week, and numbers were maintained during allergen exposure. In contrast, the kinetics of T H 2 cell generation was slower, with numbers increasing over time and continued allergen challenge (Fig 1, D) . T H 9 cells generated in vivo do not coexpress IL-10 or T H 2 or T H 1 cytokines (Fig 1, E) . Moreover, T H 9 cells did not express T1/ST2 (a surrogate marker for T H 2 cells). T H 9 cells were observed in lung cell suspensions isolated from HDM-exposed mice following ex vivo restimulation with HDM, indicating that T H 9 cells are antigen specific (Fig 1, F) . Analysis of other lymphocyte populations showed that T H 9 cells are the major source of IL-9 at this time point (see Fig  E1, B) in response to allergen challenge. A proportion of murine CD4 + IL-9 + IL-13 − cells express the transcription factor PU.1 (42.9 ± 3.9), but this was not true for all T H 9 cells ( Fig  1, G) .
These data show for the first time that T H 9 cells can be observed directly in the circulation of atopic people. Moreover, T cells differentiate in vivo into a T H 9 phenotype in response to exposure to an environmental allergen. At early time points, they are more prevalent than T H 2 cells in the lungs, indicating that they are an important effector T-cell population immediately following allergen exposure and are involved in the development of the initial immune response.
Activin A, a TGF-β family member, drives T H 9 differentiation in vitro
The cytokine activin A is a member of the TGF-β superfamily, and we have previously observed that activin A is important in driving allergic pathology in vivo, in close association with IL-25. 19 IL-25 has been shown to enhance the expression of IL-9 in T H 9 cells in vitro. 13 We therefore sought to determine whether activin A could affect T H 9 cell generation. CD3 + CD4 + cells were isolated from naive mice and activated in vitro in the presence of IL-4 in conjunction with either TGF-β1 or activin A. Addition of activin A to in vitro cultures results in the development of T H 9 cells (Fig 2, A) , replicating the effect of TGF-β1. The addition of IL-25 to IL-4/activin A-driven cultures enhanced the generation of T H 9 cells, in a similar manner to that observed in IL-4/TGF-β1-driven cultures (Fig 2, A and B; see Fig E2, A, in this article's Online Repository at www.jacionline.org). Activin Adriven T H 9 differentiated cells shared similar phenotypic characteristics to those generated in cultures with TGF-β1, in that a proportion of them expressed the transcription factor PU.1 (Fig 2, C) . Interestingly, activin A-driven T H 9 cells secrete IL-9 only in the presence of suboptimal doses (0.1 ng/mL) of TGF-β1 (Fig 2, D) . in vitro generated T H 9 cells did not coexpress IL-10 or IL-17, but they did show expression of the IL-25 receptor IL-17RB on the cell surface (Fig 2, C) . These data have implications for the generation of T H 9 cells in the lung following exposure to allergen, since TGF-β1, activin A, and IL-25 are all generated in the lung following allergen exposure in vivo and might collaborate to promote differentiation of T H 9 cells in vivo (see Fig E2, B) . These data imply that the promotion of T H 9 cells is not solely restricted to TGF-β1 but may be a function of the wider TGF-β superfamily.
Transfer of T H 9 cells in vivo promotes allergic inflammation with a mast cell phenotype
Although IL-9 is thought to play a role in the development of allergic immune responses, we wanted to determine the specific functional role that T H 9 cells exert in vivo. Therefore, we generated T H 9 cells in vitro in the presence of IL-4, IL-25, and TGF-β1 or activin A and transferred them to naive mice before exposure to HDM extract (Fig 3, A) . In vitro generated T H 9 cells expressed IL-9 but not IL-13 or IL-10, and were observed in the lungs following intraperitonial injection (see Fig E3, A and B, in this article's Online Repository at www.jacionline.org). Transfer of either activin A or TGF-β1-driven T H 9 cells to mice followed by exposure to allergen resulted in heightened allergic pathology in vivo with increased cell recruitment to the airways and lung in comparison to mice given just HDM (Fig 3, B) or T H 2 cells as a control (see Fig E3, C) . Analysis of SiglecF + granulocytes revealed that these cellular infiltrates were composed of eosinophils (Fig 3, C) . As expected, numbers of T H 2 cells were not significantly modulated by T H 9 cell transfer (Fig 3, D) .
IL-9 is thought to be important for the recruitment of mast cells to the lung and influencing the development of allergic pathology 4, 15, 20, 21 ; therefore, we measured serum levels of mast cell protease. Transfer of activin A-driven or TGF-β1-driven T H 9 cells significantly increased levels of mouse mast cell protease-1 following HDM challenge, signifying an increase in mast cell activation in these groups (Fig 3, E) . Histological analysis also revealed an increase in the numbers of intraepithelial mast cells within the lungs of mice following T H 9 cell transfer (Fig 3, F) . Transfer of T H 9 cells to HDM-treated mice was also associated with enhanced levels of serum IgE (Fig 3, G) . Moreover, ex vivo restimulation of lymphocytes with HDM revealed enhanced IL-13 and IL-9 levels in cultures from mice transferred with T H 9 cells, compared with those treated with HDM alone (Fig 3, H and I) .
Pulmonary levels of T H 2 and innate cytokines and chemokines (IL-4, IL-5 and IL-25, IL-33 thymic stromal lymphopoietin or CCL20) commonly associated with allergic responses did not change following transfer of T H 9 cells in comparison with HDM controls (data not shown).
In order to determine the specific effect of T H 9 cell transfer on the development of allergic immune responses in the absence of endogenous T H 9 differentiation, we transferred T H 9 cells into mice with severe combined immunodeficiency. T H 9 cell transfer and HDM exposure still elicited lung inflammation (Fig 3, J) , specifically the recruitment and activation of mast cells to the lung (Fig 3, K and L) . We also observed that T H 9 cells injected intraperitoneally traffic to the lungs and draining lymph nodes after exposure to HDM (see Fig E3, D) . These data show that T H 9 cells differentiated in vitro by either TGF-β1/IL-4 or activin A/IL-4 do not differ in their function in vivo and demonstrate unequivocally that T H 9 cells can promote immune responses to allergen, leading to enhanced pathology, specifically the recruitment and activation of mast cells in the lungs.
Blockade of TGF-β and activin A during primary allergen exposure in vivo reduces T H 9 differentiation and ameliorates allergic inflammation
Since we determined that TGF-β1 and activin A levels are elevated after allergen exposure and both are able to drive the differentiation of T H 9 cells in vitro, we set out to determine whether these 2 cytokines are able to affect T H 9 generation in vivo. Therefore, we used neutralizing antibodies specific for TGF-β or activin A either alone or in combination during acute allergen challenge (Fig 4, A) . The combination of anti-TGF-β and anti-activin A antibodies significantly reduced the in vivo differentiation of T H 9 cells (Fig 4, B) . In contrast, neither anti-TGF-β nor anti-activin A antibodies used alone affected the development of T H 9 cells (Fig 4, B) . Reduction of T H 9 cells by combined anti-TGF-β/ activin A antibody treatment was accompanied by a general decrease in cell recruitment to the lung (Fig 4, C) , particularly eosinophils (Fig 4, D) . Conversely, numbers of T H 2 cells were not affected by blocking TGF-β and activin A (alone or in combination) (Fig 4, E) .
Levels of serum mouse mast cell protease-1 were reduced to baseline by treatment with anti-TGF-β/activin A, and similarly mast cell recruitment to the lung was significantly decreased (Fig 4, F and G) . Combined anti-TGF-β/activin A antibody treatment considerably reduced the levels of IL-9 and IL-13 released from antigen-stimulated lymphocytes isolated from lung draining lymph nodes of allergic mice (Fig 4, H and I) .
Intriguingly, IL-25 levels in the lung were reduced to baseline values following treatment with either anti-TGF-β/activin A antibodies in combination or after anti-activin A alone (Fig 4, J) , underscoring the particular relationship between activin A and IL-25. There was no effect on levels of other proallergic cytokines and chemokines in the lung, including IL-33, thymic stromal lymphopoietin or CCL20, or classical T H 2-associated cytokines such as IL-4 and IL-5 (data not shown).
These experiments emphasize the specific role that T H 9 cells play during allergic immune responses, mediating the recruitment and activation of mast cells in the lung, and underscore the importance of the role that both TGF-β and activin A play in effecting their generation in vivo and the ensuing downstream pathology.
Long-term blockade of TGF-β and activin A in vivo leads to a reduction in mast cell-driven pathology in the lung
IL-9 is involved in the development of airway remodeling; therefore, in order to determine how blockade of the T H 9 population in vivo would affect HDM-induced AHR and airway remodeling following long-term allergen exposure, we administered a combination of anti-TGF-β and anti-activin A antibodies over 3 weeks (Fig 5, A) . Exposure of mice to inhaled HDM extract results in eosinophilic airway inflammation and AHR in association with airway remodeling, the cardinal features of asthma in humans. 19 The particular combination of anti-TGF-β and anti-activin A antibodies modulated features of airway remodeling but not inflammation. Decreased mucus production ( Fig 5, B and C) and intraepithelial mast cell numbers and activation (Fig 5, B , D, and E) were observed in antibody-treated mice when compared with isotype-treated control mice. Collagen deposition was also reduced to basal levels by long-term treatment with anti-TGF-β/activin A antibodies ( Fig 5, B and F) . In contrast, there was no effect on cell recruitment to the lung (Fig 5, G) or on the production of cytokines associated with the allergic response such as IL-4, IL-5, IL-13, IL-33, and CCL20 (data not shown). However, there was again a specific effect on IL-25, which was significantly reduced in the lung (Fig 5, H) . Importantly, there was a moderate but significant reduction in airway resistance in mice treated with combined anti-TGF-β/activin A antibodies (Fig 5, I) .
These data suggest that manipulating T H 9 cells via TGF-β/activin A affects key features of airway remodeling and AHR following allergen exposure.
DISCUSSION
Asthma is a complex heterogeneous disease thought to occur as a consequence of aberrant T H 2 immunity to innocuous environmental particles such as dust and animal dander. However, it is clear that a range of other T cells contribute to disease pathology, which might account for this heterogeneity. 22 We demonstrate here that T H 9 cells are present in human peripheral blood, since previous studies have shown IL-9 levels only in plasma or T H 9 cells generated in vitro from PBMCs. Importantly, allergic donors have higher circulating numbers of T H 9 cells when compared with nonallergic controls, which correlates with levels of plasma IgE. T H 9 cells have a key role in the development of allergic immune responses that is distinct to that played by T H 2 cells. T H 9 cells are generated early after allergen exposure and specifically promote mast cell recruitment and activation within the lung.
Activin A plays a key role in a diverse array of biological processes including fetal growth and development as well as during inflammation and tissue fibrosis. [23] [24] [25] Activin A is upregulated in the pulmonary epithelium and in peripheral blood CD4 cells following allergen challenge, in both mouse models and in allergic patients. 19, 24, 25 Expression of ALK-4, the receptor for activin A, is also increased after allergen challenge in T cells in lung biopsies from asthmatic patients. 25 Moreover, like TGF-β1, activin A exhibits both pro-and antiinflammatory properties depending on the cytokine milieu. Activin A/IL-4 elicited in vitro differentiation of T H 9 cells to a similar degree as TGF-β1, and resulted in T H 9 cells with similar characteristics. Interestingly, in vitro differentiated T H 9 cells require both TGF-β1 and activin A for optimal IL-9 secretion as previously demonstrated for IL-10 secretion from regulatory T cells. 26, 27 T H 9 cells differentiated in the presence of activin A promote the same augmentation of pathology as observed when TGF-β1-driven T H 9 cells were injected in vivo. TGF-β1 has an acknowledged role in the differentiation of a number of T-cell subsets including regulatory T cells, T H 17 cells, and T H 9 cells. 22 The data presented here indicate that activin A has a similar role, suggesting that T-cell plasticity in vivo is dependent on the wider TGF-β superfamily.
Interestingly, we have previously shown that allergen-induced expression of activin A in the epithelium is associated with IL-25 production, and the 2 cytokines cooperate to drive allergic pathology in vivo. 19 These data have implications for the generation of T H 9 cells in vivo since IL-25 augments the differentiation of T H 9 cells in vitro. 13 In the present study we show that IL-25 also enhances T H 9 generation driven by activin A and that blockade of activin A results in the suppression of IL-25. Our data emphasize the relationship between activin A and IL-25 in the allergic lung and outlines a novel pathway for the generation of T H 9 cells during allergen exposure.
IL-9 has been associated with the development of pathology during helminth infections and allergic inflammation, 8, 10 and antigen-specific T H 9 cells have been shown to induce experimental autoimmune encephalomyelitis 3 and promote moderate ocular inflammation. 18 We now provide direct evidence for the presence of T H 9 cells within the lungs. T H 9 and T H 2 cell differentiation in response to allergen challenge in vivo follows very distinct kinetics. We determined that T H 9 cells are rapidly generated in vivo following exposure of mice to inhaled HDM. In contrast, T H 2 cell differentiation and recruitment to the lung is slower, peaking 3 weeks after initial allergen exposure. Similarly, eosinophil numbers in the lung are greatest following 3 weeks of allergen challenge. This is supported by in vitro kinetic data showing that following activation, IL-9 production by polarized T H 9 cells is rapid in comparison to the production of IL-4 or IL-17 from T H 2 or T H 17 lines, respectively. 18 Taken together these results suggest that in the lung T H 9 cells may develop independently from T H 2 cells following allergen exposure and have distinct functions in vivo. Indeed, following transfer of T H 9 cells to immunocompetent or immunodeficient mice, the most striking pathologic feature of the inflammatory response was the recruitment and activation of mast cells. Adoptively transferred T H 9 cells generated in the presence of either TGF-β1 or activin A were recruited to the lung on exposure to inhaled allergen, and promoted mast cell activation as well as increased IgE levels in the serum. Similarly, numbers of circulating T H 9 cells correlated with IgE levels in human serum. IL-9 potentiates IL-4-induced IgE release from B cells 28, 29 and has been associated with mast cell function. 16 PU.1 is required for the development of IL-9-secreting T cells in mouse and human cultures in vitro. 9 However, PU.1 expression is not restricted to the T H 9 lineage and has been described as a central regulator of all hematopoietic cell lineages. 30 We found that only a proportion of in vivo generated T H 9 cells express PU.1. This was particularly evident in allergic donors where exposure to allergen was not controlled. in vivo, it is likely that while PU.1 might be essential to generate T H 9 cells, once polarized the cells do not have a requirement for continued expression. Thus, the expression of this transcription factor may fluctuate according to allergen exposure, and is not a defining feature of the T H 9 lineage.
In order to investigate the functional contribution of activin A to the in vivo development of T H 9 cells, we performed blocking studies with neutralizing antibodies to TGF-β or activin A following allergen challenge in vivo. Combined TGF-β and activin A blockade resulted in the complete abrogation of T H 9 differentiation early after allergen exposure. During prolonged allergen exposure, dual TGF-β/activin A blockade resulted in the attenuation of features of airway remodeling including mucus production and collagen deposition. AHR was also reduced as were the number of mast cells in the lung, although there was no effect on pulmonary eosinophilia following chronic HDM challenge. This reflects our recent study with an IL-9-blocking antibody, which resulted in the abrogation of mast cell recruitment with a concomitant reduction in airway remodeling, partial resolution of AHR, but no effect on classical T H 2 pathological features such as IL-13, IL-5, and eosinophilia. 4 It is important to note that these parameters were not affected by treatment with anti-TGF-β or anti-activin A antibodies given alone as previously described. 19, 31 TGF-β1 and activin A have overlapping functions in vitro and in vivo, but activin A has not previously been associated with T H 9 development. Interestingly, they share a signaling pathway via Smad3, which was identified as an asthma susceptibility gene during genomewide association studies. 32 Although long-term blockade of activin A alone had no impact on indices of inflammation, remodeling, or AHR, levels of IL-25 in the lung were significantly reduced. These data suggest a model for early events following allergen challenge with local TGF-β cooperating with epithelial-derived activin A and IL-25 to promote T H 9 generation and development of allergic pathology. Activin A has previously been postulated to be a regulator of mast cell activity in vivo. 33 Our data now indicate that the regulation of T H 9 activity by activin A may be a key driver of mast cell recruitment and activation during allergic inflammation, particularly during the early stages of the response.
In conclusion, we have shown that T H 9 cells are increased during allergic responses both in a murine model of allergic airways disease and in atopic human subjects. Our results define for the first time a functional phenotype for T H 9-driven pathology in vivo that is different but complementary to that elicited by T H 2 cells. Moreover, we provide in vitro and in vivo evidence that activin A is able to drive the differentiation of T H 9 cells. Taken together our data outline a novel pathway for T H 9 generation and identify a key functional role for T H 9 cells as a vital component of the early allergic immune response driving mast cell recruitment and activation. 
Key messages
• Circulating T H 9 cells in allergic subjects correlate with plasma IgE levels.
• Allergen induces early in vivo differentiation of pulmonary T H 9 cells.
• Novel role for activin A in driving the generation of T H 9 cells. 
